Search

Cervical cancer is a common gynecologic malignancy. Most patients with early-stage cervical cancer received unnecessary systemic pelvic lymphadenectomy, which increased the risk of surgical complications. At present, sentinel lymph node biopsy has been applied in the clinical practice of cervical cancer abroad, however it is still at the starting stage in China in need of application and promotion. The Obstetrics and Gynecology Committee of Chinese Research Hospital Association invited domestic experts in the field of gynecologic oncology to discuss the application value, patient evaluation, technical methods, operation steps, pathological examination and many other key points of sentinel lymph node biopsy based on the current research status, and reached the consensus of clinical application on sentinel lymph node biopsy in cervical cancer to guide the standardized application of the technique in China. [ABSTRACT FROM AUTHOR]

Bladder cancer is one of the common malignant tumors in China, with 75% of bladder cancer being non-muscle invasion with a high recurrence rate after surgery. Intravesical therapy is an useful methods to either directly kill tumor cells by infusing cytotoxic drugs into the bladder or directly or indirectly induce local immune responses of the body through infusing immune agents, such as bacillus calmette guerin, and thus reduce the risk of tumor recurrence and progression. In 2019, the Urological Chinese Oncology Group issued the "Expert consensus on intravesical therapy on non-muscle invasive bladder cancer". Recently, great progress in the clinical diagnosis and treatment of non-muscle invasive bladder cancer has been achieved domestically and abroad, including the risk assessment of non-muscle invasive bladder cancer, the therapeutic choice of intravesical drugs, the adverse reactions and treatment experience of intravesical therapy, and clinical research on new types of intravesical drugs. This consensus is made according to domestic and overseas evidence-based medicine in combination with current clinical practice and experience of intravesical therapy for non-muscle invasive bladder cancer in China. It is an update of the 2019 expert consensus, with the wish to provide a guidance for domestic clinical standardized intravesical therapy for non-muscle invasive bladder cancer. [ABSTRACT FROM AUTHOR]

Vascular complications after liver transplantation are important causes of liver dysfunction and graft loss. The incidence rate range is from 5% to 25%, and the mortality rate is high. The complex and changeable vascular conditions of the donor and recipient, anastomosis techniques, infection, and acute and chronic rejection after transplantation can all cause vascular complications of liver transplantation. The types of vascular complications are diverse and complex. According to the vascular structure, they can be divided into arterial and venous complications; according to the characteristics of blood flow, they can be divided into inflow tract (hepatic artery, portal vein) or outflow tract (hepatic vein, vena cava) disorders; according to the nature of the lesion, they can be divided into rupture, stenosis, thrombosis and pseudoaneurysm, etc; according to the time of occurrence, they can be divided into early or late. Surgical plan design and surgical operation techniques are the technical factors of early vascular complications after liver transplantation. The types of vascular complications and their accompanying clinical manifestations are closely related to the choice of diagnosis and treatment strategies and clinical outcomes. Therefore, the Perioperative Management Group of Chinese Society of Organ Transplantation of Chinese Medical Association formulated the Expert Consensus on Diagnosis and Treatment of Perioperative Vascular Complications of Liver Transplantation, aiming to standardize and optimize the clinical diagnosis and treatment of common perioperative vascular complications in liver transplant recipients. [ABSTRACT FROM AUTHOR]

The standardized diagnosis and treatment of tumor and the rational use of antineoplastic drugs are not only the central issue of the government and society, but also the difficulty of medical quality control. In order to implement "the Administrative Measures for the Clinical Application of Antineoplastic Drugs (Trial)" issued by the National Health Commission of the People's Republic of China, on the basis of extensive investigation and through Delphi method and several rounds of expert discussion, an expert consensus on the guiding mad map and management points of drug classification was formed. Suggestions are provided to guide other medical institutions to do the related work in the graded management of antineoplastic drugs. [ABSTRACT FROM AUTHOR]

线粒体糖尿病是由于线粒体功能缺陷引起的糖尿病, 属于特殊类型糖尿病，约占糖尿病 总数的3%。由于线粒体糖尿病存在临床表型异质性大、症状不典型、较为罕见等特点, 常被漏诊或误 诊为其他亚型糖尿病。线粒体糖尿病的临床治疗及随访不同于其他亚型糖尿病，因此，该亚型糖尿病 的及早确诊将有助于患者后续的治疗与改善临床结局。本专家共识中对国内外有关线粒体糖尿病的 研究成果与临床检验诊断策略进行总结，并提出线粒体糖尿病的临床检验诊断建议. [ABSTRACT FROM AUTHOR]

Copyright of China Journal of Oral & Maxillofacial Surgery is the property of Shanghai Jiao Tong University, College of Stomatology and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Chinese Journal of Contemporary Pediatrics is the property of Xiangya Medical Periodical Press and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Chinese Journal of Contemporary Pediatrics is the property of Xiangya Medical Periodical Press and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of West China Journal of Stomatology is the property of Sichuan University, West China College of Stomatology and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Primary medical institutions are the forefront of the diagnosis and treatment of osteoporosis. In order to solve the problems of diagnosis, treatment, and management in the process of prevention and treatment of osteoporosis in primary medical institutions, experts have compiled expert consensus on diagnosis and treatment of osteoporosis in primary medical institutions (2021) to provide reference for clinical diagnosis and treatment of osteoporosis in primary medical institutions organized by the Expert Consensus Committee on Diagnosis and Treatment of Osteoporosis in Primary Medical Institutions of China Health Promotion Foundation. The consensus indicates that osteoporosis is a systemic bone disease characterized by low bone mass, damage of bone microstructure, increase of bone fragility and easy fracture, which can be divided into primary and secondary . It is recommended that primary medical institutions conduct preliminary screening using high risk factors of osteoporosis and simple screening tools. The diagnosis of osteoporosis includes high-risk population, clinical diagnosis, and differential diagnosis. The treatment of osteoporosis includes lifestyle adjustment, basic treatment, oral and external treatment of traditional Chinese medicine, integrated traditional Chinese and Western medicine, exercise, fracture treatment, and efficacy judgment. The management of primary osteoporosis can start from population screening, data filing, hierarchical diagnosis and treatment, two-way referral, standardized treatment, and regular follow-up. [ABSTRACT FROM AUTHOR]

Bone-modifying agents currently include bisphosphonates and desumumab, which are the main drugs for the treatment of malignant tumor bone metastasis, hypercalcemia and osteoporosis. Due to its wide clinical application, the adverse events of this kind of drugs are gradually increasing and affecting the quality of life of patients. Therefore, it needs to arouse the attention of the majority of medical personnel. Based on the substantial evidence, the expert committee has thoroughly discussed the management of adverse reactions of bone modifying agents and put forward reasonable suggestions, to guide clinicians in the safety management of such drugs. [ABSTRACT FROM AUTHOR]

糖尿病神经病变是糖尿病最常见的慢性并发症, 随着糖尿病神经病变临床研究的进展, 国际上关于糖尿病神经病变的分型、诊断及治疗都有一定的更新。因此, 中华医学会糖尿病学分会神 经并发症学组组织专家们撰写了《糖尿病神经病变诊治专家共识（2021年版）》。本共识介绍了糖尿 病神经病变（主要是远端对称性多发性神经病变和自主神经病变）的流行病学、发病机制、分型、筛查 与诊断、预防及治疗, 并针对重要部分给出要点提示。本共识旨在指导和帮助临床医师对糖尿病神经 病变进行规范化的综合管理, 早期防治糖尿病神经病变, 延缓疾病进展. [ABSTRACT FROM AUTHOR]

Copyright of Chinese Journal of Cancer Biotherapy is the property of Editorial Office of Chinese Journal of Cancer Biotherapy and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Chinese Journal of Contemporary Pediatrics is the property of Xiangya Medical Periodical Press and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Breast cancer is the most common and fatal malignant tumor in women, which causes great social burden throughout the world. At present, chemotherapy is still the most important treatment manner of advanced breast cancer, and platinum drugs are one of the commonly used chemotherapeutic drugs. Based on the substantial evidence, the expert committee deeply discusses the clinical application of platinum drugs in advanced breast cancer, gives the reasonable suggestions for its clinical usage, effectiveness and adverse effects. This consensus aims to guide physicians to use drugs reasonably and standardize the diagnosis and treatment. [ABSTRACT FROM AUTHOR]

Copyright of Journal of Shanghai Physical Education Institute / Shanghai Tiyu Xueyuan Xuebao is the property of Shanghai Physical Education Institute and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

In recent years, the understanding of the essential characteristics and pathogenesis of prolonged Disorders of Consciousness (pDOC ) has been greatly promoted the evaluation and diagnosis. "The Chinese Experts Consensus on the Diagnosis and Treatment of prolonged Disorders of Consciousness" sponsored by the Disorders of Consciousness Group of the Professional Committee on Neurorepair of the Chinese Medical Association, is a compilation and summary of the experience of Chinese experts in the field of pDOC and establishes relatively uniform standards for understanding, evaluation, and implementation, which is conducive to the development of clinical and basic research on pDOC. Due to the fact that the consensus on pDOC covers many fields, there are differences and disputes among experts on the understanding and the concept of diagnosis and treatment. This paper unscrambles the key issues in the consensus writing and discussion, including the concept of "pDOC", the use of the term " VS", the Chinese translation of "MCS", the exploration and problems in functional neuro-imaging technology and electrophysiology technology, the dispute over the conservative treatment method and effect, and the choice of invasive neuromodulation treatment, and looks forward to the domestic development of pDOC diagnosis and treatment [ABSTRACT FROM AUTHOR]

Non small cell lung cancer (NSCLC) is the most common histological type of lung cancer, accounting for more than 80% of primary lung cancer. Platinum based chemotherapy is the traditional standard for the treatment of advanced NSCLC, but the 5 years survival rate is still very low, less than 5%. Angiogenesis plays an important role in the growth, proliferation and metastasis of solid tumors. Angiogenesis inhibitors affect the tumor microenvironment, degenerate existing tumor blood vessels and inhibit tumor angiogenesis. Angiogenesis inhibitors are now one of the indispensable treatments for patients with advanced NSCLC through continuous development of new angiogenesis inhibitor and improvement of drug accessibility. This consensus is based on the “Expert consensus on anti angiogenic drug therapy for advanced non small cell lung cancer in China (2019 Edition)”, combines with clinical research evidence published in the past years and clinical experience. The consensus writing group compiles a consensus of guiding clinical departments related to lung cancer treatment to use anti angiogenic drugs in a standardized manner, and further improves the level of standardized diagnosis and treatment of lung cancer. [ABSTRACT FROM AUTHOR]

Objective To explore the therapeutic efficacy and safety of elective nodal irradiation (ENI) and involved field irradiation (IFI) in intensity-modulated radiotherapy for esophageal cancer, screen the patients suitable to undergo ENI radiotherapy and provide evidences for individual treatment of esophageal cancer. Methods A retrospective analysis was performed on the clinical data of 924 patients with esophageal cancer who received definitive intensity-modulated radiotherapy in our hospital from January 2006 to December 2015. Among them, 272 patients received ENI and the other 652 patients received IFI. The clinicopathologic characteristics of 272 cases in ENI group and 652 cases in IFI group, who were recruited according to the balance of propensity score matching method, were compared. The Kaplan-Meier method was used to calculate 1-year, 3-years and 5-years local-regional failure-free survival (LRFFS), progression- free survival (PFS) and overall survival (OS) rates. The univariate and multivariate analysis of prognostic factors were also determined by Cox proportional hazard model and Long-rank test. Results The clinicopathologic characteristics of these two group were not significantly different (P>0.05). The median follow-up time was 85.9 months and the follow-up rate was 95.9%. The 1-year, 3-years, 5-years PFS rates of the ENI groups were 65.3%, 31.7%, 18.4%, respectively, higher than 54.0%, 20.9%, 12.7% of the IFI group (P =0.001). The 1-year, 3-years, 5-years OS rates of the ENI groups were 79.0%, 43.7%, 24.9%, respectively, higher than 75.0%, 31.8%, 17.2% of the IFI group (P =0.003).In multivariate analysis, the sex, tumor volume, N stage and radiation field were independent factors for PFS and OS (P < 0. 05). Subgroup analysis showed that patients with male, age=66 year, cervical and upper-thoracic location, tumor length=6 cm, T1-2 stage, N0-1 stage, --- stage, tumor volume=50 cm3, dosage>60 Gy and=2 cycles of chemotherapy in the ENI group had a better survival rate than those in the IFI group (P<0.05).The total failure rate, local-regional failure rate in ENI group were significantly lower than those of IFI group (P = 0.001, P =0.004). The incidence of bone marrow depression= grade 2 and 3 in ENI group was higher than that of the IFI group (P<0.05). However, the incidences of radioactive esophagitis= grade 3, radioactive pneumonia and late adverse reactions were not significantly different between these two groups (P>0.05). Conclusion Compared with IFI, ENI can significantly improve the long-term survival for young, early TN stage and cervical/ upper-thoracic esophageal cancer patients underwent chemotherapy. [ABSTRACT FROM AUTHOR]

Copyright of Journal of Modern Laboratory Medicine is the property of Journal of Modern Laboratory Medicine Editorial Department and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Journal of Modern Laboratory Medicine is the property of Journal of Modern Laboratory Medicine Editorial Department and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Journal of Modern Laboratory Medicine is the property of Journal of Modern Laboratory Medicine Editorial Department and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Lung cancer is by far the most common cancer and the leading cause of cancer death in China. Through multidimensional discussion and analysis of disease, the multidisciplinary team (MDT) diagnosis and treatment brings lots of benefits for cancer patients, including increasing patient satisfaction, reducing hospitalization expense, shortening treatment waiting time, providing more reasonable diagnosis and treatment pathways mHl strategics, relieving medical disputes, increasing enrollment opportunities for patients in high-quality clinical trials, patients' prognosis and life quality and so on Presently, lung cancer MDT in China needs to be improved, including guideline following, democratic decision, landing performance and feedback, meeting records, patient follow-up and so on. So this consensus combines lung cancer MDT experience of China with leading-edge global oncology MDT experience to construct patientcentered lung cancer MDT diagnosis and treatment model, including MDT responsibility and obligations, organizational framework, working modality, standard procedures, assessment methods, and encouragement mechanisms and so on. Chinese Thoracic Oncology Group; Chinese Society of Lung Cancer; Lung Cancer Group of Oncolo1gy Branch, Chinese Medical Association; Multidisciplinary Team Diagnosis and Treatment Committee, Chinses Medical Doctor Association jointly publish this consensus. The purpose of this consensus is to provide pnwedures and criteria for lung cancer MDT of China. [ABSTRACT FROM AUTHOR]

Human epidermal growth factor receptor-2 (HER-2) tyrosine kinase inhibitors (TKI) is the targeted drug of HER-2-positive breast cancer. Lapatinih, pyrotinib and neratinib, as ErbB family TKis, have been approved by National Medical Products Administration and applied in the treatment of HER-2 positive breast cancer in China. The most common adverse effects (AEs) of TKI agents include diarrhea, drug-induced liver injury (DILI), nausea, vomiting, skin toxicity, carrliotoxicity and oral mucositis. The Breast Cancer Expert Group of Chinese Society of Clinical Oncology (CSCO) summarized the incidence and characteristics of AEs of TKI, evaluated the manifostations and severity of AEs, and formulated the consensus of the management of common AEs based on the clinical experiences and updated advances from domestic and abroad studies. This consensus aims to provide the practical strategy for clinicians in the management of ErbB-family TKI-realted AEs in China, and eventually enhance the patients' compliance and improve the therapeutic efficacy. [ABSTRACT FROM AUTHOR]

Copyright of Chinese Journal of Contemporary Pediatrics is the property of Xiangya Medical Periodical Press and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

The Immune checkpoint inhibitors (ICIs) have represented a major breakthrough in the field of malignant tumor treatment. However, due to the mechanism of this novel therapy, some special forms of response modes, such as pseudoprogression and hyperprogression, have arisen, which bring difficulties and challenges to the therapeutic efficacy evaluation. In 2017, the European association of nuclear medicine reported the advantages of using 18-fluoro-2-deoxy-D-glucose (18F-FDG) PET/CT to evaluate the tumor immunotherapy response and immune-related side effects based on the published clinical trial data. In China, a large amount of research data has been generated since the clinical study of immune checkpoint inhibitors officially started in 2013.Therefore, how to utilize PET/CT reasonably and standardly in tumor immunotherapy has become an urgent clinical and scientific issue. Focusing on the practical questions of examination procedures, PET/CT image interpretation and the evaluation criteria after ICIs treatment, this consensus has been finally formed, which based on the combination of literature, expert experiences, and internal discussion among committee members in the PET Group of Chinese Society of Nuclear Medicine.This consensus is also expected to improve the guide for standardizing the application of PET/CT to evaluate tumor immunotherapy response and promoting the technology in corresponding field. [ABSTRACT FROM AUTHOR]

With the aging of the society, osteoporosis becomes one of the common diseases threatening the health of elderly population in China, and there is increasing concern on this matter. Osteoporosis is characterized with bone loss and susceptible to fragility fractures, where various imaging modalities like X-ray, CT, MRI and nuclear medicine along with bone mineral density assessment play a very important role in the diagnosis and management of osteoporosis. The treatment of osteoporosis requires multidisciplinary team work, the lack of consensus in the imaging and bone mineral density examination (BMD) of osteoporosis hampered the quality of service and patient care. Therefore, a panel consisting of experts from radiology, orthopedic, endocrinology, medical imaging and nuclear medicine reviewed the international guidelines, consensus and literature, and the newly data from China and considering the clinical practice in China, the panel reached this consensus to help guide the diagnosis of osteoporosis with imaging and BMD. This consensus will provide guideline and standard on the imaging and BMD assessment of osteoporosis and the criteria for diagnosis. [ABSTRACT FROM AUTHOR]

Copyright of Chinese Journal of Contemporary Pediatrics is the property of Xiangya Medical Periodical Press and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Objective :To establish a high-alert medication catalogue , management system，operational regulations and uniform labels for those high-alert medications ,in accordance with drug utilization features in maternal and child hospitals .Methods ：The existing high-alert medication catalogues，management systems，operational regulations and uniform labels for those high-alert medications were collected from 16 maternal and child hospitals in China .Relevant experts were called up to establish drug se¬lection standards using the Delphi method by the Pharmaceutical Management Committee of China Maternal and Child Health Care Association .Then,classifications and summaries were made specifically and a uniform and high-alert medication catalogue was compiled ,and at the same time the management system ,operational regulations and uniform labels for those high-alert medications were established .Results and Conclusion ： Through consensus of the experts ,the catalogue of those high-alert medi¬cations was established ,and the management system ,operational regulations and uniform labels for those high-alert medications suitable for use in maternal and child hospitals were drafted in the end .With it，the management of high-alert medications could be intensified from various aspects，drug management in maternal and child hospitals would be more suitable to the reality of hospitals .Therefore，it would help to lower medication risks and reduce drug-induced injuries in maternal and child hospitals. [ABSTRACT FROM AUTHOR]

As a new type of anthracyclines, pegylated liposomal doxorubicin ( PLD) is widely used in the treatment of a variety of malignant tumors, including soft tissue sarcoma, ovarian cancer,breast cancer, multiple mycloma, and so on. Compared with traditional anthracydines, PLD can significantly decrease the incidences of adverse events such as cardiac toxicity and alopecia. However, the use of PLD will he accompanied with toxic side effects such as hand-foot syndrome, oral mucositis, and infusion reaction. This consensus will mainly focus on the mechanism, prevention and treatment of adverse events of PLD, in order In improve the therapeutic efficency of PLD and lifequality of patients. [ABSTRACT FROM AUTHOR]

Copyright of China Journal of Oral & Maxillofacial Surgery is the property of Shanghai Jiao Tong University, College of Stomatology and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of China Journal of Oral & Maxillofacial Surgery is the property of Shanghai Jiao Tong University, College of Stomatology and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

In hepatobiliary carcinoma,serologic and histologic biomarkers including proteins and genes have been recommended and categorized for cancer diagnosis,targeted therapy and immunotherapy regimen selection,as well as prognostic prediction at different levels. To standardize the application of molecular biomarkers in clinical diagnosis,therapeutic evaluation,and prognosis prediction of primary hepatobiliary carcinoma,the specialist committee has summarized the current well studies biomarkers with clinical significance in both serum and tumor tissue as well as provided professional agreements on their potential utilization in this consensus. Moreover,we have made recommendations on standards for laboratory detection,technical operation,data analysis,result interpretation,clinical report,and the whole-process quality management in serological,histopathological detection and next-generation sequencing. According to these,the committee aims to offer clinical staffs with scientific and practical references and guidance to achieve better personalized treatment decisions from these up-to-date knowledges of molecular diagnosis on hepatobiliary carcinoma. [ABSTRACT FROM AUTHOR]

Stereotactic body radiation therapy (SBRT) has become an important radical approach for early stage non-small cell lung cancer, especially for patients who are inoperable or refuse surgery. In China, this precision radiotherapy technology is being popularized. In order to standardize clinical application, improve the cooperation of technology and scientific research, this expert consensus is established. The consensus includes a brief introduction to the development of SBRT, the physical and technical requirements, the clinical implementation standardization and special clinical problems. The promotion and application of the consensus in clinical practice and constantly updated according to the latest research results will benefit more and more lung cancer patients. [ABSTRACT FROM AUTHOR]

Cancer immunotherapy, especially the programmed death 1 (PD-1) and (or) programmed death ligand 1 (PD-L1) checkpoint inhibitors, has ushered in the modern oncology era and has achieved impressive success in the treatment of different tumors, including non-small-cell lung cancer (NSCLC). Yet, only a subset of patients achieved clinical benefit. Therefore, how to effectively screen the potential beneficiaries of PD-1 and (or) PD-L1 inhibitors has become a new challenge in the era of cancer immunotherapy. Clinical studies have shown that the expression level of PD-L1 in NSCLC is positively correlated with the efficacy of PD-1 and (or) PD-L1 inhibitors, and is one of the important predictive biomarkers. However, there are many challenges in PD-L1 testing. With the approving of various PD-1 and (or) PD-L1 inhibitors for immunotherapy setting of NSCLC, expert consensus of important issues regarding clinical significance of PD-L1 testing, testing time-point, as well as the standardization of PD-L1 testing procedure, including the PD-L1 testing operation steps, results' interpretation, quality control and so on, is of great significance for improving the accuracy of detection and reducing the difference between laboratories. On account to the practical questions of PD-L1 testing, this consensus was finally reached, which is based on the combination of literature, expert experience and internal discussion among committee members, in the hope of providing the guide for standardizing the PD-L1 testing and providing accurate and reliable result to screen the potential patients and predict clinical efficacy. It must be pointed out that in view of the existence of objective and complex factors of PD-L1 testing and the fact that the clinical application of PD-L1 testing is still at the early stage in China, there are still many issues need to be updated in near future based on further practice experience and research data. [ABSTRACT FROM AUTHOR]

Copyright of China Journal of Oral & Maxillofacial Surgery is the property of Shanghai Jiao Tong University, College of Stomatology and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Taxanes are cornerstones of cancer chemotherapy and can he used for the treatment of various tumors, including breast cancer. Taxane-associated peripheral neuropathy is a common adverse effect of taxanes, leading to discontinuation of drug therapy, affecting drug treatment outcomes, and severely affecting patients quality of life. This consensus addresses and recommends the pathogenesis, clinical features, associated risk factors, diagnostic evaluation, prevention, and treatment of tax

Breast cancer is the most common malignant tumor among women. Taxanes are one of the most frequently used chemotherapy regimens for breast cancer. In order to guide clinicians rational use of taxanes mid further standardize the diagnosis mid treatment of breast cancer, the expert group proposed this "Expert consensus on the clinical practice of taxanes for the treatment of breast cancer" based on substantial evidence and thorough discussion. [ABSTRACT FROM AUTHOR]

Melanoma is one of the common and serious malignant tumors clinically. The mortality and morbidity of melanoma patients showed a rapid growing tendency in recent years though the incidence was low in China. Normalized surgical treatment is not only the key to curing the early and intermediate stage melanoma, but also conducive to the better prognosis for advanced patients. According to Chinese national conditions, the soft tissue sarcoma and melanoma expert committee of Chinese Anti-cancer Association defined this expert consensus on the surgical treatment of cutaneous/acral melanoma based on the guidelines for melanoma diagnosis and management of Chinese Society of Clinical Oncology (CSCO). It was also referred to clinical practice guidelines in cutaneous melanoma of National Comprehensive Cancer Network (NCCN), clinical practice guidelines for the management of melanoma in Australia and New Zealand as well as relevant domestic and foreign clinical researches and meta-analysis. The expert consensus includes normalized details and operational key points in each part of surgical treatment of cutaneous/acral melanoma, which aims to generalize the normalized surgical treatment, reach the purpose of surgical treatment, and ultimately improve patients′ prognosis. [ABSTRACT FROM AUTHOR]

Copyright of Journal of Shanghai Physical Education Institute / Shanghai Tiyu Xueyuan Xuebao is the property of Shanghai Physical Education Institute and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of China Journal of Oral & Maxillofacial Surgery is the property of Shanghai Jiao Tong University, College of Stomatology and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Chinese Journal of Contemporary Pediatrics is the property of Xiangya Medical Periodical Press and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Lung cancer is the most common cancer and the leading cause of cancer death in China, with 733 thousands estimated new lung cancer cases and 610 thousands deaths in 2015. In the pathological type of lung cancer, non-small cell lung cancer (NSCLC) accounts for 80%-85%, and 30% of NSCLC patients have already reached stage III at diagnosis, who have lost the optimal opportunity for surgical treatment. Stage III NSCLC is highly heterogeneous, the 5-year survival rates of stage III A, III B and III C NSCLC are 36%, 26% and 13%, respectively. For the great complexity of making decisions in the clinical practice of stage III NSCLC, the experts of this consensus group combine the latest clinical research results and cutting-edge multidisciplinary concepts, conduct in-depth and detailed discussions on the hot issues and controversies in the diagnosis, treatment and follow-up surveillance of stage III NSCLC. Chinese Anti-Cancer Association and Committee of Lung Cancer Society jointly publish this consensus to provide guidance for Chinese clinicians. [ABSTRACT FROM AUTHOR]

Ｔｈｅ ｉｎｃｉｄｅｎｃｅ ｏｆ ｒｅｔｒｏｐｅｒｉｔｏｎｅａｌ ｔｕｍｏｒ ｉｓ ｌｏｗ， ａｎｄ ｔｒｅａｔｍｅｎｔ ｉｓ ｄｉｆｆｉｃｕｌｔ．Ａｃｃｏｒｄｉｎｇ ｔｏ ｔｈｅ ｒｅｃｅｎｔ ｕｐｄａｔｅｓ ｏｆ ｅｖｉｄｅｎｃｅ⁃ｂａｓｅｄ ｍｅｄｉｃａｌ ｅｖｉｄｅｎｃｅ ａｔ ｈｏｍｅ ａｎｄ ａｂｒｏａｄ， ｔｈｅ ｃｏｎｓｅｎｓｕｓ ｏｎ ｔｈｅ ｓｔａｎｄａｒｄｉｚｅｄ ｔｒｅａｔｍｅｎｔ ｏｆ ｒｅｔｒｏｐｅｒｉｔｏｎｅａｌ ｔｕｍｏｒｓ ｗｅｒｅ ｄｉｓｃｕｓｓｅｄ ｉｎｃｌｕｄｉｎｇ ｅｘａｍｉｎａｔｉｏｎ ａｎｄ ｄｉａｇｎｏｓｉｓ ，ｓｕｒｇｉｃａｌ ｔｒｅａｔｍｅｎｔ ｃｏｍｐｒｅｈｅｎｓｉｖｅ ｔｒｅａｔｍｅｎｔ， ｎｕｔｒｉｔｉｏｎ， ｒｅｈａｂｉｌｉｔａｔｉｏｎ， ａｎｄ ｒｅｖｉｅｗ ａｎｄ ｆｏｌｌｏｗ⁃ｕｐ， ｅｔｃ． [ABSTRACT FROM AUTHOR]